CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (180,629,000)	$ (24,545,000)
Net loss	(195,234,000)	(25,162,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	13,041,000	4,581,000
Impairment of intangible assets	6,720,000	0
Share-based compensation	32,921,000	5,176,000
Deferred income taxes	717,000	1,166,000
Unrealized loss on equity securities	40,968,000	0
Other, net	2,378,000	2,694,000
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(29,221,000)	(23,188,000)
Direct contracting performance year receivable	(638,641,000)	0
Other assets	(22,270,000)	(15,707,000)
Medical cost payable	337,180,000	225,814,000
Risk adjustment payable	354,276,000	137,215,000
Accounts payable and other liabilities	52,182,000	30,096,000
Unearned revenue	(18,402,000)	918,000
Direct contracting performance year obligation	533,537,000	0
Net cash provided by operating activities	484,757,000	343,603,000
Cash flows from investing activities:
Purchases of investments	(782,091,000)	(298,957,000)
Proceeds from sales, paydown, and maturities of investments	154,765,000	265,521,000
Purchases of property and equipment	(5,491,000)	(4,215,000)
Business acquisitions, net of cash acquired	(310,000)	(18,624,000)
Net cash used in investing activities	(633,127,000)	(56,275,000)
Cash flows from financing activities:
Proceeds from issuance of preferred stock	747,481,000	0
Proceeds from issuance of common stock	257,000	4,893,000
Proceeds from short-term borrowings	0	200,000,000
Repayments of short-term borrowings	(155,000,000)	0
Payments for debt issuance costs	0	(3,391,000)
Payments for IPO offering costs	0	(1,268,000)
Net cash provided by financing activities	592,738,000	200,234,000
Net increase in cash and cash equivalents	444,368,000	487,562,000
Cash and cash equivalents – beginning of year	1,061,179,000	488,371,000
Cash and cash equivalents – end of period	1,505,547,000	975,933,000
Supplemental disclosures of cash flow information:
Changes in unrealized (loss) gain on available-for-sale securities in OCI	(26,340,000)	(1,042,000)
Cash paid for interest	1,168,000	244,000
Supplemental schedule of non-cash activities:
Redeemable convertible preferred stock issued for acquisitions	$ 0	$ 32,982,000